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CONCLUSION AND OUTLOOK 
 
This thesis describes several approaches to new molecular solutions for light-activated 
pharmacotherapy and targeted medical imaging. On the one hand, the presented 
research shows molecules for different applications that undergo structural changes 
upon irradiation with an appropriate wavelength. More precisely, light is used to control 
(i) multifunctional photocages for potential use as drug targeting systems (CHAPTER 2), 
(ii) the permeability of liposomes (CHAPTER 4), and (iii) the relaxivity of T1 MRI contrast 
agents (CHAPTER 4 and 5). On the other hand, in the case of the fluorescent tracers for 
optical imaging reported in CHAPTER 6 and 7, light plays a role as read-out modality to 
assess the specific localization of the respective probes.  
Overall, our investigations set the base for new approaches to signal amplification in 
MRI, image-guided drug therapy and selective optical imaging. However, the reported 
methods are mostly at a proof-of-concept stage and there are still various limitations 
to overcome for their successful clinical application. Towards this end, one overarching 
task is to enable the use of light that is minimally absorbed in biological tissue. This 
need served as an inspiration for developing new synthetic methods for red-light 
responsive photocages of the reported liposomal MRI contrast agent (CHAPTER 4). 
Unfortunately, the synthesis of the photocleavable conjugates proved to be problematic 
and future research should focus on the implementation of alternative synthetic 
strategies or photoactive groups to overcome this challenge. 
Another point to consider is that the MRI probes reported in CHAPTER 4 and 5 operate 
as “switch-off” agents. In order to facilitate image interpretation and minimize false 
positive outcomes, improved contrast agents that show a signal increase upon 
irradiation, preferably from a completely silent “off” to an MR active “on” state, have to 
be established. This will be possible by employing new, emerging MRI modalities like 
chemical saturation exchange transfer (CEST) imaging. This method relies on the 
detection of exchangeable protons, which can be pre-saturated selectively. With respect 
to the development of photoresponsive structures, we for instance conceive the 
development of a caged contrast agent, which would possess an additional 
exchangeable proton only after cleavage of the photoprotecting group. 
As already indicated, the next step in the optimization of the fluorescent probes 
reported in CHAPTER 6, will be to shift their absorption and emission maxima to higher 
wavelength. This can be achieved through the substitution of the fluorescent moiety by 
NIR-light absorbing tracers, as already reported for one of the examples (Ampho-
800CW, CHAPTER 7). However, even though red- and NIR light penetrates much deeper 










into biological tissue, the possible imaging depth is still limited as compared to e.g. MRI 
or CT. In order to tackle this challenge, improved modalities based on optical imaging 
have been developed. In particular, optoacoustic imaging, relying on the detection of 
acoustic waves emitted as a consequence of the thermal relaxation of light absorbing 
structures (photoacoustic effect), was shown to significantly increase imaging depth 
while still affording high resolution images. We envision that the implementation of 
targeted tracers for this method will substantially improve its diagnostic power and 
therefore respective probes ought to be developed in the future. 
Furthermore, prospective research should focus on the implementation of theranostic 
probes, such as the conjugate of vancomycin with IRdye700DX. This probe offers the 
unique possibility of functioning as a fluorescent probe and singlet oxygen producer, 
allowing the simultaneous detection and selective treatment based on photodynamic 
therapy (PDT) of Gram-positive bacterial infections that are usually difficult to treat, like 
for example multi-resistant Staphylococcus aureus (MRSA). 
Nevertheless, even when red- or NIR-light is used for activation and/or imaging, the 
penetration and imaging depth is not infinite. Therefore, the irradiation source has to 
be brought as close as possible to the target tissue and the molecules that are to be 
activated. Hence, it is of equal importance to simultaneously investigate in the 
development of tools to deliver light to the human body.  
The use of light in medicine has been established as standard therapy over the last 
century, for instance since the 1960s for the treatment of neonatal hyperbilirubinemia, 
and the corresponding field of research is constantly advancing. To date, treatments 
such as laser therapy or photodynamic therapy are well established in dermatology, 
ophthalmology but also gastroenterology or urology with the help of endoscopic 
setups. Beyond those clinically implemented systems, many more advanced 
technologies have emerged in recent years. Those are for instance implantable 
(biodegradable) devices or bioluminescent moieties. Especially the latter are of 
outstanding interest for our research purposes as outlined in CHAPTER 4. 
With the development of improved light-responsive probes, as well as innovative light 
delivery systems, we believe in the great potential of photo-activated drug therapy and 
molecular imaging. Notably, the success of those approaches strongly relies on the 
collaborative efforts of researchers and clinicians from different disciplines, such as, 
amongst others, (bio-)chemistry, medicine, pharmacy, physics and engineering. 
Therefore, it is of paramount importance to align the several fields of research and work 
conjointly in order to obtain the best possible (clinical) outcomes. 
